Recent progress in the development of anthrax vaccines

Recent Patents on Biotechnology

Volumn 5, Issue 3, 2011, Pages 148-159

  Kaur, Manpreet ^a,b   Bhatnagar, Rakesh ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b An Autonomous Institute of Department of Biotechnology   (India)

Author keywords

In vivo challenge; Lethal toxin; Neutralizing antibodies; Protection; Protective antigen; Therapeutics; Vaccines

Indexed keywords

ANTIBODIES; BACTERIA; BACTERIOLOGY; DISEASES; EPITOPES; IMMUNIZATION;

ANTHRAX VACCINES; B.ANTHRACIS; IN VIVO CHALLENGE; IN-VIVO; LETHAL TOXIN; NEUTRALIZING ANTIBODIES; PROTECTION; PROTECTIVE ANTIGENS; RECENT PROGRESS; THERAPEUTIC;

VACCINES;

ANTHRAX VACCINE; ANTIBIOTIC AGENT; ANTIGEN; DNA VACCINE; DOXYCYCLINE; GENTAMICIN; IMIPENEM; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IQNPA 1; MONOCLONAL ANTIBODY IQNPA 2; NEUTRALIZING ANTIBODY; OFLOXACIN; PLACEBO; POLYCLONAL ANTIBODY; PROTECTIVE ANTIGEN; RECOMBINANT ANTIGEN; RECOMBINANT PROTECTIVE ANTIGEN VACCINE; RECOMBINANT THROMBOPOIETIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTHRAX; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; BACILLUS ANTHRACIS; BACTERIAL MEMBRANE; BACTERIAL SPORE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BIOLOGICAL WARFARE AGENT; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; EARLY INTERVENTION; EPIZOOTIOLOGY; GENE DELIVERY SYSTEM; GENE EXPRESSION SYSTEM; GENETIC ENGINEERING; HETEROLOGOUS EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; LACTOBACILLUS ACIDOPHILUS; LETHAL GENE; MUCOSAL IMMUNITY; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROTECTION; PROTEIN DOMAIN; PROTEOMICS; RECOMBINANT DNA TECHNOLOGY; REVIEW; SURVIVAL RATE; SYSTEMIC DISEASE; TRANSGENIC PLANT; TREND STUDY; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION;

BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS);

EID: 80054106949     PISSN: 18722083     EISSN: None     Source Type: Journal    
DOI: 10.2174/187220811797579097     Document Type: Review

References (140)

1. Mock M, Fouet A. Anthrax. Annu. Rev. Microbiol. 2001; 55: 647-671.
2. Leppla SH, Robbins JB, Schneerson R, Shiloach J. Development of an improved vaccine for anthrax. J. Clin. Investig. 2002; 110: 141-144.
3. Greenfield RA, Drevets DA, Machado LJ, Voskuhl GW, Cornea P, Bronze MS. Bacterial pathogens as biological weapons and agents of bioterrorism. Am. J. Med. Sci. Jun. 2002; 323: 299-315.
4. Mourez M. Anthrax toxins. Rev Physiol Biochem Pharmacol. 2004; 152: 135-64.
5. James JA, Farris D, Crowe S. Anthrax compositions and methods of use and production. US7794732, 2010.
6. Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. 2001; 7: 933-944.
7. Guarner J, Jernigan JA, Shieh WJ, et al. Pathology and pathogenesis of bioterrorism-related inhalational anthrax. American Journal of Pathology 2003; 163: 701-709.
8. Quinn CP, Dull PM, Semenova V, et al. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorismrelated cutaneous or inhalation anthrax. J Infect Dis. 2004; 190: 1228-36.
9. Mercier CL, JR. Terrorists, WMD, and the US Army Reserve. Parameters 1997: pp. 98-118.
10. Xu M, Humphreys RE. Ii-key/antigenic epitope hybrid peptide vaccines. US0291145, 2010.
11. Rasko DA, Alther MR, Han CS, Ravel J. Genomics of the Bacillus cereus group of organisms. FEMS Microbiol Rev 2005; 29: 303-29.
12. Vilas-Boas GT, Peruca APS, Arantes OMN. Biology and taxonomy of Bacillus cereus, Bacillus anthracis, and Bacillus thuringiensis. Can J Microbiol 2007; 53: 673-87.
13. Chitlaru T, Altboum Z, Reuveny S, Shafferman A. Progress and novel strategies in vaccine development and treatment of anthrax. Immunological Reviews 2011; 239: 221-36.
14. Brey RN. Molecular basis for improved anthrax vaccines. Adv. Drug Deliv. Rev. 2005; 57: 1266-1292.
15. Mourez MD, Lacy B, Cunningham K, et al. 2001: A year of major advances in anthrax toxin research. TRENDS in Microbiology 2002; 10: 287-93.
16. Stanley JL, Smith H. Purification of factor I and recognition of a third factor of the anthrax toxin. J. Gen. Microbiol. 1961; 26: 49-63.
17. Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998; 280: 734-737.
18. Vitale G, Pellizzari R, Recchi C, Napolitani G, Mock M, Montecucco C. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem Biophys Res Commun. 1998; 248: 706-11.
19. Leppla SH. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA 1982; 79: 3162-3166.
20. Eisner M. Use of adjuvants for obtaining antibodies against capsule polypeptides of Bacillus anthracis. Schweiz Z Pathol Bakteriol. 1959; 22: 129-44.
21. Ostroff G, Axelrod Dr, Bovarnick M. Antigenicity of polymers of glutamyl peptide on humans. Proc Soc Exp Biol Med. 1958; 99: 345-7.
22. Kubler-Kielb J, Liu T, Mocca C, Majadly F, Robbins JB, Schneerson R. Additional Conjugation Methods and Immunogenicity of Bacillus anthracis Poly-γ-d-Glutamic Acid-Protein Conjugates. Infect Immun. 2006; 74: 4744-4749.
23. Ezzell J, Abshire T, Little S, Lidgerding B, Brown C. Identification of Bacillus anthracis by using monoclonal antibody to cell wall galactose- N-acetylglucosamine polysaccharide. J Clin Microbiol 1990; 28: 223-31.
24. Collier RJ, John AT. Young. Anthrax Toxin. Annu Rev Cell Dev Biol. 2003; 19: 45-70.
25. Dixon T, Meselson M, Guillemin J, Hanna P. Anthrax. New Engl J Med. 1999; 341: 815-826.
26. Lane HC, Montagne JL, Fauci AS. Bioterrorism: a clear and present danger. Nat. Med. 2001; 7: 1271-1273.
27. Weiss S, Kobiler D, Levy H, Pass A, Ophir Y, Rothschild N, et al. Antibiotics cure anthrax in animal models. Antimicrob Agents Chemother. 2011; 55: 1533-42.
28. Wilson GS, Miles A. In: Topley and Wilson's principles of bacteriology, virology and immunity; 1975: pp. 2220-2221.
29. Wright GG. In: Dubos RJ, Hirsch JG, Eds. The anthrax bacillus. Bacterial and mycotic infections of man. Philadelphia: Lippincott Williams & Wilkins 1965: pp. 530-544.
30. Ivins BE, Ezzell JW Jr, Jemski J, Hedlund KW, Ristroph JD, Leppla SH. Immunization studies with attenuated strains of Bacillus anthracis. Infect Immun. 1986; 52: 454-8
31. Barnard JP, Friedlander AM. Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen. Infect Immun. 1999; 67: 562-7.
32. Ariel N, Zvi A, Makarova KS, et al. Genome-based bioinformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens. Infect Immun. 2003; 71: 4563-79.
33. Gat O, Mendelson I, Chitlaru T, et al. The solute-binding component of a putative Mn(II) ABC transporter (MntA) is a novel Bacillus anthracis virulence determinant. Mol Microbiol. 2005; 58: 533-51.
34. Turnbull PCB. Anthrax vaccines: past, present and future. Vaccine 1991; 9: 533-539.
35. Shlyakhov EN, Rubinstein E. Human live anthrax vaccine in the former USSR. Vaccine 1994; 12: 727-730.
36. Cohen S, Mendelson I, Altboum Z, et al. Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect Immun. 2000; 68: 4549-58.
37. Brossier F, Levy M, Mock M. Anthrax spores make an essential contribution to vaccine efficacy. Infect Immun. 2002; 70: 661-4.
38. Aloni-Grinstein R, Gat O, Altboum Z, Velan B, Cohen S, Shafferman A. Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen. Infect Immun. 2005; 73: 4043-53.
39. Auerbach S, Wright GG. Studies on immunity in anthrax. VI. Immunizing activity of protective antigen against various strains of Bacillus anthracis. J. Immunol. 1955; 75: 129-133.
40. Puziss M, Wright GG. Studies on immunity in anthrax. X. Geladsorbed protective antigen for immunization of man. J. Bacteriol. 1962; 85: 230-236.
41. Puziss M, Manning LC, Lynch JW, Barclay E, Abelow I, Wright GG. Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures. Appl. Microbiol. 1963; 11: 330-334.
42. Ivins BE, Fellows PF, Nelson GO. Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea pigs. Vaccine 1994; 12: 872-4.
43. Ivins BE, Pitt MLM, Fellows PF, et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 1998; 16: 1141-1148.
44. Fellows PF, Linscott MK, Ivins BE, et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 2001; 19: 3241-3247.
45. Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham NR. Field evaluation of a human anthrax vaccine. Am J Public Health 1962; 52: 632-645.
46. Brachman PS, Friedlander AM. In: Plotkin SA, Orenstein WA, Eds. Anthrax. Vaccines 3rd Ed. Philadelphia: Saunders WB 1999: pp. 629-37.
47. Shlyakhov E, Rubinstein E, Novikov I. Anthrax post-vaccinal cell mediated immunity in humans: kinetics pattern. Vaccine 1997; 15: 631-6.
48. McBride BW, Mogg A, Telfer JL, et al. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 1998; 16: 810-818.
49. Doling AM, Ballard JD, Shen H, et al. Cytotoxic T-lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity. Infect Immun 1999; 67: 3290-6.
50. Fowler K, McBride BW, Turnbull PC, Baillie LW. Immune correlates of protection against anthrax. J Appl Microbiol 1999; 87: 305.
51. Brossier F, Weber-Levy M, Mock M, Sirard JC. Protective antigen mediated antibody response against a heterologous protein produced in vivo by Bacillus anthracis. Infect Immun. 2000; 68: 5731-4.
52. Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigen specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004; 286: 111-22.
53. Escuyer V, Collier RJ. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells. Infect. Immun. 1991; 59: 3381-86.
54. Elliott JL, Mogridge J, Collier RJ. A quantitative study of the interactions of Bacillus anthracis edema factor and lethal factor with activated protective antigen. Biochemistry 2000; 39: 6706-13.
55. Flick-Smith HC, Walker NJ, Gibson P, Bullifent H, Hayward S, Miller J, et al. A recombinant carboxy-terminal domain of the pro tective antigen of Bacillus anthracis protects mice against anthrax infection. Infect Immun 2002; 70: 1653-6.
56. Singh Y, Ivins BE, Leppla SH. Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis. Infect. Immun. 1998; 66: 3447-3448.
57. Gupta P, Waheed SM, Bhatnagar R. Expression and purification of the recombinant Protective antigen of Bacillus anthracis. Protein Expression and Purification 1999; 16: 369-376.
58. Chawla A, Midha S, Bhatnagar R. Efficacy of recombinant anthrax vaccine against Bacillus anthracis aerosol spore challenge: Preclinical evaluation in Rabbits and Rhesus monkeys. Biotechnology Journal 2009; 4: 1-9.
59. Shiloach J, Leppla SH, Ramirez DM, Schneerson R, Robbins JB, Hsu SD, Rosovitz MJ. Methods for preparing Bacillus anthracis protective antigen for use in vaccines. US7763451, 2010.
60. Wui SR, Kim HK, Han JE, et al. A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice. Int Immunopharmacol. 2011; Available online Apr 12 [Epub ahead of print].
61. Brahmbhatt TN, Darnell SC, Carvalho HM, et al. Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen. Infect. Immun. 2007; 75: 5240-5247.
62. Wang JY, Roehrl MH. Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin. Medical Immunology 2005; 4: 4-11.
63. Hambleton P, Turnbull PCB. Anthrax vaccine development: a continuing story. Adv. in Biotechnol. Processes 1990; 13: 105-122.
64. Petosa C, Collier RJ, Klimpel KR, Leppla SH, Liddington RC. Crystal structure of the anthrax toxin protective antigen. Nature 1997; 385: 833-838.
65. Little SF, Novak JM, Lowe JR, et al. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 1996; 142: 707-715.
66. Varughese M, Teixeira AV, Liu S, Leppla SH. Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin. Infect. Immun. 1999; 67: 1860-1865.
67. Brossier F, Sirard JC, Guidi-Rontani C, Duflot E, Mock M. Functional analysis of the carboxy-terminal domain of Bacillus anthracis protective antigen. Infect. Immun. 1999; 67: 964-967.
68. Krishnanchettiar S, Sen J, Carey M. Expression and purification of the Bacillus anthracis protective antigen domain 4. Protein Expression and Purification 2003; 27: 325-330.
69. Pezard C, Weber M, Sirard JC, Berche P, Mock M. Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect Immun 1995; 63: 1369-72.
70. Shivachandra SB, Li Q, Peachman KK, et al. Multicomponent anthrax toxin display and delivery using bacteriophage T4. Vaccine 2007; 7: 1225-1235.
71. Campbell JD, Clement KH, Wasserman SS, Donegan S, Chrisley L, Kotloff KL. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum Vaccine 2007; 3: 205-211.
72. Friedlander AM, Little SF. Advances in the development of next generation anthrax vaccines. Vaccine 2009; 27: 28-32.
73. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nature Reviews Drug Discovery 2007; 6: 404-414.
74. Kaur M, Chug H, Singh H, et al. Identification and characterization of immunodominant B-cell epitope of the C-terminus of Protective Antigen of Bacillus anthracis. Molecular Immunology 2009; 46: 2107-2115.
75. Cease KB, Oscherwitz J. Epitope targeted anthrax vaccine. WO2010080188, 2010.
76. Adams S, Albericio F, Alsina J, Smith ER, Humphreys RE. Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class II molecules. Arneimittelforschung 1997; 47: 1069-1077.
77. Xu M, Jackson R, Adams S, Humphreys RE. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1. Arzneimittelforschung 1999; 49: 791-9.
78. Humphreys RE, Adams S, Koldzic G, Nedelescu B, von Hofe E, Xu M. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine 2000; 18: 2693-2697.
79. Humphreys RE. Methods of enhancing or antigen presentation to T cells inhibiting. US5559028, 1996.
80. Humphreys RE, Adams S, Xu M. Ii peptide therapeutics to enhance antigen presentation. US5919639, 1999.
81. Humphreys RE, Adams S, Xu M. Hybrid peptides modulate the immune response. US6432409, 2002.
82. Chabot DJ, Scorpio A, Tobery SA, Little SF, Norris SL, Friedlander AM. Anthrax capsule vaccine protects against experimental infection. Vaccine 2004; 23: 43-7.
83. Joyce J, Cook J, Chabot D, et al. Immunogenicity and protective efficacy of Bacillus anthracis poly- γ-d -glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy. J Biol Chem 2006; 281: 4831-43
84. Aziz MA, Singh S, Kumar PA, Bhatnagar R. Expression of protective antigen in transgenic plants: a step towards edible vaccine against anthrax, Biochem. Biophys. Res. Commun. 2002; 299: 345-351.
85. Watson J, Koya V, Leppla SH, Daniell H. Expression of Bacillus anthracis protective antigen in transgenic chloroplasts of tobacco, a non-food /feed crop, Vaccine 2004; 22: 4374-4384.
86. Aziz MA, Sikriwal D, Singh S, Jarugula S, Kumar PA, Bhatnagar R. Transformation of an edible crop with the pagA gene of Bacillus anthracis, FASEB J. 2005; 19: 1501-1503.
87. Koya V, Moayeri M, Leppla SH, Daniell H. Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge, Infect. Immun. 2005; 73: 8266-8274.
88. Gorantala J, Grover S, Goel D, et al. A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax. Vaccine 2011; 29: 4521-33.
89. Chichester JA, Musiychuk K, de la Rosa P, et al. Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine 2007; 25: 3111-4.
90. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu. Rev. Immunol. 1997; 15: 617-648.
91. Shedlock DJ, Weiner DB. DNA vaccination: antigen presentation and the induction of immunity. J. Leukoc. Biol. 2000; 68: 793-806.
92. Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282: 476-80.
93. MacGregor RR, Boyer JD, Ugen KE, et al. First human trial of a DNA based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host responses. J. Infect. Dis. 1998; 178: 92-100.
94. Mulligan MJ, Russell ND, Celum C, et al. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses 2006; 22: 678-83.
95. Price BM, Liner AL, Park S, Leppla SH, Mateczun A, Galloway DR. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun 2001; 69: 4509-15.
96. Hermanson G, Whitlow V, Parker S, et al. A cationic lipidformulated plasmid DNA vaccine confers sustained antibodymediated protection against aerosolized anthrax spores. Proc Natl Acad Sci U S A. 2004; 101: 13601-13606.
97. Sloat BR, Cui Z. Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles. Pharm Res. 2006; 23: 262-9.
98. Ribeiro S, Rijpkema SG, Durrani Z, Florence AT. PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice. Int J Pharm. 2007; 331: 228-32.
99. Park YS, Lee JH, Hung CF, Wu TC, Kim TW. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect Immun. 2008; 76: 1952-9.
100. Midha S, Bhatnagar R. Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses. European Journal of Immunology 2009; 39: 159-77.
101. Chitlaru T, Gat O, Gozlan Y, Grosfeld H, Inbar I, Shafferman A. Identification of in vivo expressed immunogenic proteins by sero logical proteome analysis of Bacillus anthracis secretome. Infect Immunol 2007; 75: 2841-2852.
102. Keller MA, Stiehm ER. Passive Immunity in Prevention and Treatment of Infectious Diseases. Clinical Microbiology Reviews 2000; 13: 602-614.
103. Kulshreshtha P, Bhatnagar R. Inhibition of anthrax toxins with a bispecific monoclonal antibody that cross reacts with edema factor as well as lethal factor of Bacillus anthracis. Mol Immunol. 2011; Jun 23, Epub ahead of print.
104. Groen H, Cool-Kebbedies C, Slopsema KS, Westra H. Human Anthrax Toxin Neutralizing Monoclonal Antibodies And Methods Of Use Thereof. US7658925, 2010.
105. Brossier F, Levy M, Landier A, Lafaye P, Mock M. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect Immun 2004; 72: 6313-7.
106. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000; 132: 364-8.
107. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 3241-8.
108. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100: 3457-69.
109. Springhorn JP, David G. Antibodies containing therapeutic TPO/EPO mimetic peptides. WO2010099019, 2010.
110. Kozel TR, Murphy WJ, Brandt S, et al. mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia. Proc Natl Acad Sci U S A 2004; 101: 5042-7.
111. Kozel TR, Thorkildson P, Brandt S, et al. Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect Immun. 2007; 75: 152-63.
112. Chen Z, Purcell RH, Schneerson R, Kubler-Kielb J, Dai LZ. Monoclonal antibodies that react with the capsule of Bacillus anthracis. WO2010077473, 2010.
113. Chen Z, Schneerson R, Lovchik J, et al. Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule. Proc Natl Acad Sci U S A. 2011; 108: 739-44.
114. Vor dem Esche U, Huber M, Zgaga-Griesz A, et al. Passive vaccination with a human monoclonal antibody: Generation of antibodies and studies for efficacy in Bacillus anthracis infections. Immunobiology 2011; 216: 847-853.
115. Little SF, Webster WM, Fisher DE. Monoclonal antibodies directed against protective antigen of Bacillus anthracis enhance lethal toxin activity in vivo. FEMS Immunol Med Microbiol. 2011; 62: 11-22.
116. Duc le H, Hong HA, Atkins HS, et al. Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigen. Vaccine 2007; 25: 346-55.
117. Mohamadzadeh M, Duong T, Sandwick SJ, Hoover T, Klaenhammer TR. Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge. Proc Natl Acad Sci U S A. 2009; 106: 4331-6.
118. Mohamadzadeh M, Durmaz E, Zadeh M, et al. Targeted expression of anthrax protective antigen by Lactobacillus gasseri as an anthrax vaccine. Future Microbiol. 2010; 5: 1289-96.
119. Okinaka R, Cloud K, Hampton O, et al. Sequence, assembly and analysis of pX01 and pX02. J Appl Microbiol. 1999; 87: 261-2.
120. Read TD, Peterson SN, Tourasse N, et al. The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria. Nature 2003; 423: 81-6.
121. Bambini S, Rappuoli R. The use of genomics in microbial vaccine development. Drug Discov Today 2009; 14: 253-260.
122. Shafferman A, Ordentlich A, Velan B. In: The challenge of highly pathogenic microorganisms, mechanisms of virulence and novel medical countermeasure. Reverse vaccinology in B. anthracis. Netherlands: Springer 2010: pp. 295-306.
123. Gat O, Grosfeld H, Ariel N, et al. Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen. Infect Immun. 2006; 74: 3987-4001.
124. Gat O, Grosfeld H, Shafferman A. In: Grandi G Ed. In vitro transcription and Translation Protocols. In vitro screen of bioinformatically selected Bacillus anthracis vaccine candidates by coupled transcription, translation and immunoprecipitation analysis. Totowa, New Jersey, USA: Humana Press. Methods Mol Biol 2007: pp. 211-233.
125. Chitlaru T, Gat O, Gozlan Y, Ariel N, Shafferman A. Differential Proteomic Analysis of the Bacillus anthracis Secretome: Distinct Plasmid and Chromosome CO2-Dependent Cross Talk Mechanisms Modulate Extracellular Proteolytic Activities. J. Bacteriol. 2006; 188: 3551-3571.
126. Mesnage S, Tosi-Couture E, Mock M, Gounon P, Fouet A. Molecular characterization of the Bacillus anthracis main S-layer component: evidence that it is the major cell-associated antigen. Mol Microbiol 1997; 23: 1147-1155.
127. Fouet A, Mesnage S, Tosi-Couture E, Gounon P, Mock M. Bacillus anthracis surface: capsule and S-layer. J Appl Microbiol 1999; 87: 251-255.
128. Fouet A, Mesnage S. In: Koehler T Ed. Anthrax. Bacillus anthracis cell envelope components. Netherlands: Springer Verlag, Curr Top Microbiol Immunol 2002: pp. 87-113.
129. Fouet A. The surface of Bacillus anthracis. Mol Aspects Med 2009; 30: 374-385.
130. Mesnage S, Tosi-Couture E, Mock M, Fouet A. The S-layer homology domain as a means for anchoring heterologous proteins on the cell surface of Bacillus anthracis. J Appl Microbiol. 1999; 87: 256-60.
131. Sára M, Sleytr UB. S-Layer proteins. J Bacteriol. 2000; 182: 859-68.
132. Mesnage S, Fontaine T, Mignot T, Delepierre M, Mock M, Fouet A. Bacterial SLH domain proteins are non-covalently anchored to the cell surface via a conserved mechanism involving wall polysaccharide pyruvylation. EMBO J. 2000; 19: 4473-4484.
133. Mesnage S, Tosi-Couture E, Mock M, Fouet A. The S-layer homology domain as a means for anchoring heterologous proteins on the cell surface of Bacillus anthracis. J. Appl. Microbiol. 1999; 87: 256-260.
134. Mignot T, Mesnage S, Couture-Tosi E, Mock M, Fouet A. Developmental switch of Slayer protein synthesis in B. anthracis. Molec Microbiol 2002; 43: 1615-1627.
135. Steichen CT, Kearney JF, Turnbough CL Jr. Characterization of the exosporium basal layer protein BxpB of Bacillus anthracis. J Bacteriol. 2005; 187: 5868-76.
136. Hahn UK, Boehm R, Beyer W. DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components. Vaccine 2006; 24: 4569-71.
137. Brahmbhatt TN, Darnell SC, Carvalho HM, et al. Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen. Infect Immun. 2007; 75: 5240-7.
138. Kern JW, Schneewind O. BslA, a pXO1-encoded adhesin of Bacillus anthracis. Mol Microbiol. 2008; 68: 504-15.
139. BslA, the S-layer adhesin of B. anthracis, is a virulence factor for anthrax pathogenesis. Kern J, Schneewind O. Mol Microbiol. 2010; 75: 324-32.
140. Ebrahimi CM, Kern JW, Sheen TR, et al. Penetration of the bloodbrain barrier by Bacillus anthracis requires the pXO1-encoded BslA protein. J Bacteriol. 2009; 191: 7165-73.